Recent Advances in Kawasaki Disease by 김규연 & 김동수
15www.eymj.org
INTRODUCTION
Kawasaki disease (KD) was first reported in 1967 by T. Kawa-
saki, a Japanese pediatrician.1 The first Korean KD patient was 
reported in 1973.2 Since then, the incidence of this disease has 
increased continuously. KD is characterized with acute sys-
temic vasculitis that occurs predominantly in children be-
tween 6 months to 5 years of age. Although the clinical symp-
toms of KD are well characterized, the causes of this disease 
are not yet known. For this reason, KD is usually diagnosed by 
clinical symptoms, such as a fever for 5 days or more, bilateral 
nonpurulent conjunctival congestion, changes of the lips and 
oral mucosa, polymorphous exanthema along the trunk, 
changes of the peripheral extremities and subsequent des-
quamation of finger tips, and nonpurulent cervical lymph-
adenopathy over 1.5 cm in size (Table 1). Other than these cri-
teria, erythema on Bacille Calmette-Guérin (BCG) vaccination 
sites is also thought to be an important finding in children 
younger than the age of 2 years.3 This is an especially impor-
tant finding for KD patients in Korea, since BCG vaccination is 
included in a national immunization program (NIP) during 
the neonatal period.
Patients with this disease recover well, and the disease is 
self-limited in most cases. However, since it can lead to devas-
tating cardiovascular complications, KD carries great clinical 
importance and needs special attention. Among cardiovascu-
lar complications, coronary artery lesions in particular can 
lead to long term morbidity and mortality. Without proper 
treatment in a timely manner during the acute phase of coro-
nary artery complications, about 20% of patients develop cor-
onary artery aneurysm. Giant aneurysm, with a diameter ex-
ceeding 8 mm, is known to develop in about 0.5–1% of KD 
patients. Once a giant aneurysm is formed, recovery is almost 
impossible and can result in coronary stenosis, obstruction, 
or acute thrombosis. These complications cause ischemic 
heart disease and/or myocardial infarction later and may also 
cause rare but fatal sudden cardiac death in children.4,5 In par-
ticular, occurrence of myocardial infarction results in poor 
prognosis with reported mortality after the first myocardial 
infarction at 22% and with subsequent episodes of myocardial 
infarction causing 70–80% mortality.6
In developed countries, including South Korea, incidences 
of congenital heart disease are significantly diminishing, al-
though KD still ranks as the most common cause for acquired 
heart disease in children. In fact, the prevalence of KD in South 
Korea is second only to Japan. Recent reports show steady in-
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Update on KD
creases in the prevalence of KD per 100000 children less than 
5 years old: 86.4 in 2000 to 2002, 105.0 in 2003 to 2005, 113.1 in 
2006 to 2008, and 134.4 in 2011. Hence, KD is not regarded as 
a rare disease.7 Interestingly, while Japan and South Korea 
show continuous increase in incidence,7 United States and 
Canada showed constant prevalences without increase.8
The etiology of KD has been studied extensively, and viral 
or bacterial infections, autoimmune factors, and genetic fac-
tors have been suggested. It is noteworthy to mention high 
prevalence of KD in children between 6 months and 5 years 
old, when maternal immune function decreases. Other points 
to note include a self-limited clinical course without specific 
treatment and the epidemic nature of occurrence patterns. 
These points raise suspicions of an infectious disease; however, 
specific pathogens have yet to be found.
Almost 50 years have passed since KD was first recognized. 
Recent advances in research on KD include searches for ge-
netic susceptibility related to KD and research on immuno-
pathogenesis based on the idea that innate immunity has a 
more prominent role than the acquired immunity. Also, search 
for etiopathogenesis and treatment of KD has been actively 
sought after using animal models. This paper will present the 
recent progress of research on KD.
GENETIC SUSCEPTIBILITY RELATED TO 
KD 
In understanding the pathophysiology of KD, genetic suscep-
tibility has received much attention owing to the likely occur-
rence patterns in specific races and families. According to 
data published in 2005, incidence rates per 100000 children 
under age of 5 were 134.2 for Japan, 104.6 for Korea, and 66 for 
Taiwan, compared to reports of 18.5 in US, 8.1 in UK, and 6.2 
in Sweden. Also, according to reports of an epidemiological 
survey in California, US from 1995 to 1999, the incidence rate 
per 100000 children under the age of 5 years old was 15.3. 
However, the incidence rates according to ethnic background 
were as follows: 35.3 for Asians, 24.6 for Blacks, 14.7 for Cau-
casians, 9.6 for Hispanics, and 8.6 for Native Americans.9 In an 
epidemiology survey taken in Hawaii from 1996 to 2001, inci-
dence rates per 100000 children under the age of 5 were 35.3 
for Caucasians and 197.7 for Japanese living in Hawaii. This 
incidence rate for Japanese children was even higher than the 
incidence rate in Japan and shows that prevalence among 
races is clearly different.10
Reports also have been made on family history. Matsubara, 
et al.11 have reported KD occurred five times in three siblings 
among one family within 6 years. Several studies have found 
incidence rates among siblings to be 1.4 to 2.1%; this is much 
higher than that for the general population.12,13 Also, as the first 
generation patients with initial KD go into reproductive years, 
increasing incidences in their children, a familial incidence 
rate, have been reported.14 These differences in ethnicity and 
family suggest genetic factors play a strong role in the devel-
opment of KD.
Initial research on genetic susceptibility has mainly focused 
on human leukocyte antigen (HLA) and allotypes of immuno-
globulin. HLA-DRB1, HLA B5, Bw51, and Bw4415-18 and kappa-
chainallotype Km1 and heterozygocity of Km1 with Gm and 
etc.19 are reported in association with susceptibility to KD. 
Huang, et al.20 reported HLA-DRB1 is not associated with coro-
nary aneurysm in Taiwanese patients, and Barron, et al.21 re-
ported that no association could be found between HLA class 
II allele and KD.
Recently, many studies on various genes associated with 
different immunologic reactions among diverse groups have 
been undertaken. Associations with ethnicity, region, and 
gender have shown different results, and have been interpret-
ed as differences in genetic background among ethnic groups. 
Searches for genes associated with KD are still ongoing and 
Table 2 lists the candidate genes that have been studied to 
date.22,23
Ongoing genetic research has sought to find associations 
with susceptibility to KD, severity of KD, contraindications to 
Table 1. Criteria for Diagnosis of KD
Fever for 5 days or more, plus four of the following five
1.  Changes of the peripheral extremities 
 Erythema of the palms and soles, diffuse edema of the hands and feet 
 Subsequent desquamation of the fingertips
2. Polymorphous exanthema
3. Bilateral nonpurulent conjunctival congestion
4.  Changes of the lips and oral mucosa 
 Red, dry, cracked lips, strawberry tongue, injection of the oral and  
   pharyngeal mucosa
5. Acute, nonpurulent cervical lymphadenopathy >1.5 cm in size
KD, Kawasaki disease.
Table 2. Candidate Genes Associated with KD22,23
Cytokines
IL-1β, IL-1Ra, IL-4, IL-6, IL-10, IL-18, MCP-1, TGFB2, TGFBR2, SMAD
Chemokines
CXCR1, CXCR2, CX3CR1, CCR2, CCR3, CCR5, CCL3LI
Matrix metallopeptidases
MMP2, MMP3, MMP9, MMP12, MMP13, TIMP2
Fc fragment of IgG, low affinity
FCGR2A, FCGR2B, FCGR3A, FCGR3B
HLA
Bw15, Bw22J, Bw22J2, Bw44, Bw51, B35, B37, Cw09, DRB3*031+
Others
MTHFR, CRP, SLC11A1, UGT1A1, AGTR1, VEGFA, VEGF2, ACE, HMOX1,
   CD14, CD40, MICA, PAFAH, eNOS, iNOS, MBL
KD, Kawasaki disease.
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immunoglobulin treatment, and development of coronary ar-
tery complications. With the start of genome-wide association 
studies (GWAS), remarkable progress has been made. Cur-
rently, the most interesting candidates of KD-susceptibility 
genes are the inositol 1,4,5-triphosphate 3-kinase (ITPKC) 
gene, caspase-3 (CASP3) gene, B lymphocyte kinase (BLK), 
CD40 gene, Fc fragment of IgG low affinity IIa receptor (FC-
GR2A), and HLA. Recent reports from meta-analysis of GWASes 
from Japan, Taiwan, and Korea have shown that the above 
genes hold significant value within these three countries (Ta-
ble 3).24 Differences in single nucleotide polymorphisms (SNPs) 
of genes, excluding previously reported SNPs of ITPKC genes 
by Onouchi,25 were reported. Onouchi25 also reported different 
risk allele frequencies among Japan, Taiwan, and Europe 
populations, which reflect differences between ethnicity.
Japan shows the highest incidence of KD worldwide, and a 
nationwide GWAS was executed on 78 families with KD among 
siblings. The results showed the strongest associations in 
12q24 and 19q13.2 regions.26 In 2008, this research team sur-
veyed and analyzed 1222 SNPs from 1671 Japanese individu-
als (KD patients: 637, normal control: 1034) and 209 family 
members with a family history of KD. In doing so, functional 
SNPs with highly significant associations with KD were found 
in ITPKC, which is present in the 19q13.2 region of the human 
chromosome. This result was also confirmed through family 
analysis. These results showed similar trends in not only Japa-
nese, but American children as well. Thereafter, the functional 
SNP found and analyzed by the study has been reported to 
have a high susceptibility to KD and to increase risk of coro-
nary complications in both Eastern and Western popula-
tions.27
ITPKC, which is a secondary messenger molecule involved 
in the Ca++/NFAT signal pathway, acts as a negative regulator 
of T-cell activation. ITPKC polymorphism results in increased 
activation of T cells with an increased expression of cytokines.27 
This can result in more prolonged expansion of proinflamma-
tory T cells during the acute phase, which may lead to KD sus-
ceptibility and disease severity.
However, in Koreas, researchers have yet to find a signifi-
cant polymorphism of ITPKC genes. Rather, the rs4236089 C 
allele in chloride intracellular channel 5 (CLIC5), located at 
6p21.1, has been reported to be very important.28 This discrep-
ancy may be because Japanese and Americans have different 
genetic backgrounds than Koreans. Reports from Taiwan also 
show differences in polymorphism incidences of ITPKC genes 
attributed to differences in ethnicity.29 Interestingly, Taiwan 
study results showed an association between ITPKC gene 
polymorphism and erythema of BCG vaccination sites. This 
observation requires further investigation to see whether other 
gene polymorphisms exert synergistic effects.
Onouchi, et al.30 also reported that a SNP within the CASP3 
gene located on 4q34-35 was associated with KD susceptibili-
ty by a positional candidate gene study. This was significantly 
associated with KD susceptibility in both Japanese and Euro-
American populations. CASP3 is associated with apoptosis of 
immature cells. The G to A substitution within exon 1 of CASP3 
(rs113420705) reduces the binding of NFAT to the DNA sur-
rounding the SNP and then decreases the transcription of 
CASP3 mRNA, which in turn activates immune cells to in-
crease cytokines expression. This might lead to increased sus-
ceptibility of KD. However, CASP3 gene polymorphism has not 
been shown to be associated with development of coronary 
arterial lesion (CAL) or inadequate response to IVIG. 
Interestingly, functional SNPs in both ITPKC and CASP3 
genes confer unresponsiveness of patients to IVIG and risk for 
CAL.31 This might be from synergistic effects of genetic vari-
ants of ITPKC and CASP3, which could be observed in other 
diseases.32,33 Based on these results, administration of cyclo-
sporine A for the treatment of IVIG-resistant KD patients is 
theoretically feasible, because cyclosporine A suppresses acti-
vation of NFAT. Currently, cyclosporine A is already being 
used34 in treatment and further research projects are ongoing.
Another study showed a strong association for the suscepti-
bility of KD with rs1801274 on FCGR2A.35 FCGR2A is expressed 
on the surface of various immune cells, such as dendritic cells, 
monocytes, macrophages, and neutrophils, and transduces 
activation signals into the cell when ligated with immune com-
plexes.36 Evidence of immune activation during the acute 
phase of KD might be activated upon signaling through FC-
GR2A ligation with circulating immune complex, which can 
be found in the sera of KD patients.37
In 2012, two GWAS studies35,38 independently reported sig-
nificant associations with KD that were observed in the FA-
M167A-BLK region on chromosome 8p23-p22. The associa-
tion peak in this locus was located at the intergenic region 
between BLK and FAM167A. BLK is a src family tyrosine ki-
Table 3. Novel Susceptibility Locus for KD from the Meta-Analysis of Three GWASes24 
Gene SNP p value SNP (Onouchi)25
ITPKC rs28493229 3.07×10-9 rs28493229
CASP3 rs2720377 2.66×10-9 rs113420705
BLK rs2736340 1.23×10-16 rs2254546
CD40 rs1883832 1.76×10-8 rs4813003
HLA class 2 rs189914842 4.57×10-11 rs2857151
KD, Kawasaki disease; GWASes, genome-wide association studies; SNP, single nucleotide polymorphism; ITPKC, inositol 1,4,5-triphosphate 3-kinase; CASP3, 
caspase-3; BLK, B lymphocyte kinase; HLA, human leukocyte antigen.
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nase expressed mainly in B cells and involved in B cell receptor 
signal transduction.39 This may indicate possible involvement 
of B cells for the development of KD.40,41 Moreover, BLK is re-
quired in the development of IL-17-producing γδT cells in 
mice.42 During the acute phase of KD, increased IL-17 levels 
have been reported,43 which might be associated with poly-
morphism of BLK. This might be associated with dysregula-
tion of Th17/Treg cell imbalance in patients in patients with 
KD.44 However, the function of FAM167A molecule is unclear. 
The association KD and SNPs around CD40 located on chro-
mosome 20q12-q13.2 have also been reported in a Japanese 
GWAS38 and a Taiwanese GWAS.45 CD40 is expressed on B 
cells, as well as on monocytes/macrophages, endothelial cells, 
epithelial cells, smooth muscle cells, fibroblasts, and adipo-
cytes. Following activation, its receptor, CD40L is upregulated. 
Elevated expression of CD40L during the acute phase of KD 
and significantly higher expression thereof in KD patients with 
CALs have been reported.46 It is likely that CD40-CD40L signal 
pathways may play a facilitating role in the disease progression 
of KD and could be a novel target of molecular therapies.
The association of HLA alleles with susceptibility to diseas-
es, especially autoimmune diseases, is well known. Recently, 
a significant association of the SNPs in the HLA class II region, 
HLA-DQB2, and HLA-DOB, with KD was reported.38 
IMMUNOPATHOGENESIS 
Striking immune derangement has been reported to occur in 
acute KD, including various changes of immune cells, marked 
cytokine cascade stimulation, and endothelial cell activation 
(Table 4).
As shown in Table 4, many kinds of proinflammatory cyto-
kines and chemokines are increased during the acute phase of 
KD. The key processes leading to coronary arteritis are still be-
ing clarified, although endothelial cell activation, activation of 
CD68+ monocytes/macrophages, CD8+ T lymphocytes, and 
oligoclonal IgA plasma cells appear to be involved in the de-
velopment of coronary artery arteritis.48-50 The infiltration of 
IgA plasma cells in the respiratory tract, which is similar to 
findings in fatal viral respiratory infections, suggests a respira-
tory portal entry of an etiologic agent or agents.51 Rodó, et al.52 
suggested that a KD agent is transported by the wind, possibly 
from a shared source region, across the Pacific. This hypothe-
sis may support the plausibility of the entry of causative agents 
through the respiratory tract leading to the development of 
KD. Enzymes, such as MMPs,53,54 that are capable of damaging 
arterial cell wall integrity could be important in the develop-
ment of aneurysmal dilatation of coronary arteries. CD40L, 
VGEF, MCP-1, and various cytokines also could play impor-
tant roles in the development of vasculitis.46,55-60 With these re-
Table 4. Evidence of Derangement of the Immune System in Acute KD 
(Modified from Kim47)
Cytokines
TNF-α, TNF-β, p60 soluble TNF-R, IL-1β, IL-2, soluble IL-2R, IL-4, IL-6, IL-8, 
  IL-10, IL-15, IL-17, IL-18, IL-20, IFN-α, IFN-γ, TGF-β
Chemokines
MIP-1, MCP-1β, MIF, RANTES
T lymphocytes
DR+ CD4 and CD8, Vβ2 and Vβ8 T cells, CD40L, Imbalance  
  of Th17/Treg cells
B lymphocytes
Activated B cells spontaneously secreting Ig, cytotoxic IgM Ab to  
  endothelial cells
Circulating immune complex, Ab to EBV, Ab to 65kD HSP, Ab to  
  thrombin-III, Ab to ANCA
Oligoclonal expansion of VκIII and VH, CD5+ B cells
Monocytes/macrophages
Increased number of activated cells, TLR2, VEGF
KD, Kawasaki disease; TLR2, toll-like receptor 2.
Table 5. The History of Animal Models of KD (Modified from Chun, et al.67)
Researchers Animal Inducers Results
Murata66 DD an DDY mice CAWS Coronary arteritis
Lehman, et al.68 C57BL/6, BALB/c mice Group B Lactobacillus Coronary arteritis
Felsburg, et al.69 Young dogs Naturally occurred Necrotizing vasculitis
Onouchi, et al.70 Weanling rabbits Serum sickness Coronary arteria dilatation
Duong, et al.71 C57BL/6, BALB/c mice Group B Lactobacillus casei cell wall extract Coronary arteritis
Takahashi, et al.72
CD-1, C57BL/6N, C3H/HeN, DBA/2N, 
  CBA/JN, BALB/c mice
CAWS Systemic vasculitis
Ohno73 DBA/2, C3H/HeN mice CAWS Coronary arteritis
Nakamura, et al.74 C57BL/6 mice BCG crude extract of M. intracellulare Autoimmune vasculitis
Schulte, et al.75 C57BL/6, RAG1-/- B6, B-null mice Group B Lactobacillus casei cell wall extract Coronary arteritis





KD, Kawasaki disease; CAWS, Candida albicans water soluble fraction; BCG, Bacille Calmette-Guérin.
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sults, Kim47 proposed important roles of acquired immune 
events in the development of vasculitis in KD.
Meanwhile, increased expression of toll-like receptor 2 
(TLR2) on the peripheral blood monocytes suggests that in-
nate immunity may be involved in the pathogenesis of KD.61 
Ikeda, et al.62 also reported that innate immunity may be in-
volved in the pathogenesis or pathophysiology of vasculitis in 
KD. Nishio, et al.63 reported that the pathological findings of 
Nod1 ligand-induced coronary arteritis in mice were consis-
tent with those of human coronary artery lesions in the acute 
phase of KD. With this result, they suggest that the innate im-
mune system could play an important role in the develop-
ment of KD. Kusuda, et al.64 reported that serum KD-specific 
molecules possess molecular structures common to microbe-
associated molecular pattern (MAMP) from Bacillus cereus, 
Bacillus subtilis, Yersinia pseudotuberculosis, and Staphylococ-
cus aureus, and these molecules decreased after treatment 
with IVIG. Dr. Hara65 proposed that increased MAMPS and 
damage-associated molecular patterns (DAMPs) in the sera of 
acute phase patients with KD activate the immune system and 
vascular cells through innate immune pattern recognition re-
ceptor (PRR) to release chemokines and cytokines, thereby in-
ducing KD in genetically predisposed individuals.
 
 
ANIMAL MODELS OF KD
Researchers have faced some obstacles in outlining the etio-
pathogenesis and treatment modalities for KD. First, usually 
KD patients come to the hospital after development of full-
blown clinical symptoms. Thus, clinical samples can only be 
obtained from progressed stages of the disease. Second, tissue 
biopsy from coronary arteries, in which the most important 
complication of the disease occurs, cannot be obtained easily. 
Also, tissue samples of coronaries from autopsy are rare. Third, 
due to the peak incidence at an early age, collecting blood 
samples from KD patients and obtaining informed consent 
from guardians are difficult. For these reasons, development 
of animal models of KD is needed. 
In 1979, Murata66 developed the first animal model of KD in 
DD and DDY strains of mice induced by Candida albicans wa-
ter soluble fraction (CAWS). After this report, much effort has 
been made to develop various animal models of KD (Table 5).67
Taken together with the results of research from murine 
models of KD, Takahashi, et al.76 suggested a hypothesis for the 
development of vasculitis. Upon α-mannan binding to Dec-
tin-2, Syk activates NF-kB. The NF-kB activates cytokine genes, 
including pro-IL-1β, IL-23, and IL-12. These cytokines stimu-
late differentiation of Th17 cells. Via Th17 cells, neutrophils 
and macrophages are recruited to inflammatory sites, stimu-
lating the production of various pro-inflammatory cytokines 
and chemokines. Also, various cytokines and chemokines 
stimulate the activation of endothelial cells and vascular 
smooth muscle cells. Inflammatory cells adhere to activated 
endothelium and migrate within the vascular wall. Thereby, 
vasculitis develops. Motomura, et al.77 recently reported car-
diac CD11C+ macrophages, especially, play a pivotal role in the 
development of acute coronary arteritis in FK565-treated 
mice. This suggests innate immunity is important to the de-
velopment of coronary vasculitis in KD. Nevertheless, further 
studies are needed to clarify the etiopathogenesis of KD.
CARDIAC SEQUELAE
Generally, KD patients without known cardiac sequelae dur-
ing the first month of KD appear to return to their previous 
(usually excellent) state of health without signs or symptoms 
of cardiac impairment.78 However, identification of appropri-
ate long term follow-up of these patients has proven difficult, 
because no clear picture of the potential sequelae of the disease 
without coronary artery aneurysms has emerged. Some au-
thors have suggested that KD survivors involve increased arte-
rial stiffness and are more likely to develop hypertension.79,80 A 
Japanese registry study showed that for KD patients, mortality 
after the acute phase of the disease is increased only in males 
with early cardiac lesions, such as aneurysms. However, this 
group had a standardized mortality ratio of 2.6, with the major 
cause of death arising from noncardiac origins.81,82 Recently, 
Holve, et al.83 also reported that long-term cardiac outcomes 
encompass a low rate of adverse cardiovascular events up to 
age 21. Meaningful knowledge about long-term myocardial 
function, late-onset valvular regurgitation, and coronary ar-
tery status in this population awaits careful surveillance in the 
future decades.
CONCLUSION
Though almost 50 years has passed since KD was first recog-
nized, many topics remain to be clarified, including etiology, 
immunopathogenesis, genetics, development of coronary ar-
tery aneurysms, treatment of IVIG resistant patients, and 
long-term cardiac sequelae. In the future, overcoming KD will 
reflect the efforts of many researchers in various fields. 
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